Skip to main content

ChEMBL Is Alive! Part 1 - posted by Louisa


'ChEMBL Is Alive' is to show that ChEMBLdb is a living database that is constantly being worked on by a number of people. As the Chemical Curator for ChEMBL, I (Louisa Bellis) thought it would be interesting for our Blog readers to find out what goes on behind the scenes at 'ChEMBL Towers' and to get regular updates on what we are doing to the data between releases and in response to user emails sent to chembl-help@ebi.ac.uk.

As well as being the chemical curator, I also deal with most of the help-desk traffic, where users can email in and let us know of any errors that they may have found, or even to suggest an improvement or enhancement for the interface.

As an example of the work that is done to ChEMBL on an ongoing basis, I thought it would be good to give a brief summary of some of the chemical curation that occurred during the month of June 2012:

An external user pointed out to me that they had come across a 'few' compounds that had the same canonical SMILES string, but had different standard InChI strings. I created a spreadsheet of these duplicate SMILES, which came to a whopping 967 lines. Of these, just over 100 lines were due to E/Z isomerism, some needed to be merged for being incorrect and the rest were checked individually to see why the SMILES were the same. It turned out that there was an issue with the molfiles so each of these compounds was redrawn from scratch. This came to 1,112 compound redraws in all which will be loaded into ChEMBL as soon as possible and will be visible to external users in the ChEMBL_15 release (expected end of November 2012).

I also started working on a list of duplicate names in the ChEMBL database. This was to support my own work flow and not suggested by our users - it created a list of 9,952 duplicate names. However, not all duplicate names are actual duplicates that need to be merged together, they can simply have the same simple chemical name that is not reflecting that they are enantiomers of each other. This work is still ongoing, but I have been able to redraw and merge about 100 compounds as a direct result of this list. I am only about 10% of the way through this spreadsheet, so I can say that it will keep me busy for a little while yet.

In June, we also received two emails from users to let us know that they had found what they believed were errors. In one case, the units had been incorrectly extracted from the paper as nM, when they were in fact uM. Upon checking the paper, I could see where the confusion had arisen. I could see that it had one table where they displayed uM and all the rest of the tables were nM, so the extractor had not seen this difference. These have now been fixed and will be visible in ChEMBL_14 (due for release end of July 2012).

The other email I'll mention here was to do with target assignment, where we had assigned a target to some data, and the user had read the paper and believed that the data was incorrectly assigned. This is still being checked by our biological curator, but if found to be incorrect, will be changed immediately in the database.

These are both great examples of users helping us to improve the quality of data in ChEMBL.

I hope to add more curation information in the future, but if there is anything specific that you would like to see me blog about (relating to curation or error checking) then please let me know.

Comments

Thierry said…
Hi Louisa,

Thanks for the cool update and the impressive demonstration of transparency.

Thierry
Noel O'Boyle said…
Likewise - see it's not just me, Louisa! :-)
Louisa said…
Thanks for the positive comments. If there is something specific that you would like me to write about, please just let me know.

thanks

Louisa

Popular posts from this blog

ChEMBL 34 is out!

We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains:         2,431,025 compounds (of which 2,409,270 have mol files)         3,106,257 compound records (non-unique compounds)         20,772,701 activities         1,644,390 assays         15,598 targets         89,892 documents Data can be downloaded from the ChEMBL FTP site:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/ Please see ChEMBL_34 release notes for full details of all changes in this release:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/chembl_34_release_notes.txt New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding vaccines). 71 out of the 882 newly added EMA drugs are only authorised by EMA, rather than from other regulatory bodies e.g.

New SureChEMBL announcement

(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f

Accessing SureChEMBL data in bulk

It is the peak of the summer (at least in this hemisphere) and many of our readers/users will be on holiday, perhaps on an island enjoying the sea. Luckily, for the rest of us there is still the 'sea' of SureChEMBL data that awaits to be enjoyed and explored for hidden 'treasures' (let me know if I pushed this analogy too far). See here and  here for a reminder of SureChEMBL is and what it does.  This wealth of (big) data can be accessed via the SureChEMBL interface , where users can submit quite sophisticated and granular queries by combining: i) Lucene fields against full-text and bibliographic metadata and ii) advanced structure query features against the annotated compound corpus. Examples of such queries will be the topic of a future post. Once the search results are back, users can browse through and export the chemistry from the patent(s) of interest. In addition to this functionality, we've been receiving user requests for  local (behind the

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d

New Drug Approvals - Pt. XVII - Telavancin (Vibativ)

The latest new drug approval, on 11th September 2009 was Telavancin - which was approved for the treatment of adults with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria , including Staphylococcus aureus , both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains. Telavancin is also active against Streptococcus pyogenes , Streptococcus agalactiae , Streptococcus anginosus group (includes S. anginosus, S. intermedius and S. constellatus ) and Enterococcus faecalis (vancomycin susceptible isolates only). Telavancin is a semisynthetic derivative of Vancomycin. Vancomycin itself is a natural product drug, isolated originally from soil samples in Borneo, and is produced by controlled fermentation of Amycolatopsis orientalis - a member of the Actinobacteria . Telavancin has a dual mechanism of action, firstly it inhibits bacterial cell wall synthesis by interfering with the polymerization and cross-linking of peptid